European Registry of Next Generation Imaging in Advanced Prostate Cancer
About this study
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form. Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.
- Condition
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Tested
- Imaging
- Sponsor
- Fundacio Puigvert
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Adult male patients (≥18 years with no upper age limit).
- Histologically proven prostate cancer.
- Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
- Patients who authorize their participation in the study by signing a written informed consent form (ICF).
Exclusion 3
- Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
- Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
- Patients who will not be able to complete the study.
Where
24 sites, 24 recruiting
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Fundació Puigvert
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Spain
Universitair Ziekenhuis Leuven
Leuven, Belgium
Hospital Center University De Lille
Lille, France
and 18 more sites on ClinicalTrials.gov
Contact
-
Francesco Sanguedolce, MD, PhD
+34934169100 fsanguedol@fundacio-puigvert.es
-
Daria Chernysheva, MD, PhD
+34672034192 daria.chern@gmail.com
Potential match only. Final eligibility is determined by the study team.